Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia

Summary

This is an open, two arms, mask phase I clinical study to evaluate efficacy and safety of two different chimeric antigen receptor T cell immunotherapies (Senl\_1904A and Senl\_1904B) targeting cluster of differentiation antigen 19 （CD19） in the treatment of Acute lymphocytic Leukemia. A total of 20 patients are planned to be enrolled following up half a year.

Timeline

Start

2019-01-02

Primary completion

2021-09-01

Completion

2022-01-31

Publications

• Ho JY, Wang L, Liu Y, Ba M, Yang J, Zhang X, Chen D, Lu P, Li J. Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo. Mol Ther Methods Clin Dev. 2021 Mar 13;21:237-246. doi: 10.1016/j.omtm.2021.03.007. eCollection 2021 Jun 11.

Drugs

Indications